The effect of hesperidin supplementation on indices of glucose and lipid, insulin levels and insulin resistance in patients with type 2 diabetes: a randomized double-blind clinical trial

Diabetes mellitus is a common chronic disease and a major public health problem globally. This study was performed to investigate the effect of hesperidin supplementation on markers of glucose and lipid, insulin levels and insulin resistance.
Forty-five patients with type 2 diabetes participated in this randomized, doubleblind controlled clinical trial. Subjects consumed 500 mg/d hesperidin supplement in the intervention group (n=23) and 500 mg/d placebo in the control group (n=22), for 8 weeks. Blood samples and dietary recall questionnaire were obtained at the baseline and end of study. The levels of Fasting Blood Glucose (FBG), insulin, hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), and insulin resistance were measured and compared. Statistical analyses were conducted with SPSS software by using independent t test and Paired t test.
Hesperidin supplementation led to significant decrease in FBG (p=0.04) and HbA1c (p=0.02) levels in compared to control group. A significant increase in serum insulin and decrease in TC (p=0.01 and p=0.04, respectively) were observed in the hesperidin group after the intervention, whereas no significant changes in the placebo group were observed at baseline and at the end of the study.
The present study showed that the intake of hesperidin could lead to decreased levels of FBG, HbA1c and TC and increased levels of insulin in patients with type 2 diabetes.